Información de Vertex Pharmaceuticals Inc, dividendo de Vertex Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de Vertex Pharmaceuticals Inc Compañía

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Información de Vertex Pharmaceuticals Inc



Símbolo de cotizaciónVRTX

Nombre de la empresaVertex Pharmaceuticals Inc

Fecha de salida a bolsaJul 24, 1991

Director ejecutivoKewalramani (Reshma)

Número de empleados6100

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 24

Dirección50 Northern Avenue

CiudadBOSTON

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal02210

Teléfono16173416393

Sitio Webhttps://www.vrtx.com/

Símbolo de cotizaciónVRTX

Fecha de salida a bolsaJul 24, 1991

Director ejecutivoKewalramani (Reshma)

Ejecutivos de Vertex Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

47.80K

+28.61%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

--

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

35.24K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

29.50K

+12.65%

Ms. Joy Liu

Corporate Secretary

20.73K

-5.33%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

17.74K

-112.72%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

13.66K

-78.45%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.92K

+12.69%

Ms. Jennifer J. Schneider

Independent Director

1.39K

-23.24%

Mr. Michel Lagarde

Independent Director

1.13K

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

47.80K

+28.61%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

--

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

35.24K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

29.50K

+12.65%

Ms. Joy Liu

Corporate Secretary

20.73K

-5.33%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

17.74K

-112.72%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

TRIKAFTA

10.31B

86.15%

ALYFTREK

837.80M

7.00%

Other CF products

820.10M

6.85%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

7.55B

63.06%

Europe

3.46B

28.91%

Other

992.40M

8.29%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

TRIKAFTA

10.31B

86.15%

ALYFTREK

837.80M

7.00%

Other CF products

820.10M

6.85%

Estadísticas de accionistas

Actualizado: dom., 10 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

Capital World Investors

10.05%

Capital Research Global Investors

6.82%

Vanguard Capital Management, LLC

6.51%

BlackRock Institutional Trust Company, N.A.

6.00%

State Street Investment Management (US)

4.61%

Otro

66.01%

Accionistas

Proporción

Capital World Investors

10.05%

Capital Research Global Investors

6.82%

Vanguard Capital Management, LLC

6.51%

BlackRock Institutional Trust Company, N.A.

6.00%

State Street Investment Management (US)

4.61%

Otro

66.01%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

60.15%

Investment Advisor/Hedge Fund

28.02%

Pension Fund

2.27%

Research Firm

2.19%

Bank and Trust

2.05%

Sovereign Wealth Fund

1.33%

Hedge Fund

1.27%

Individual Investor

0.17%

Insurance Company

0.08%

Otro

2.47%

Participación institucional



Actualizado: mié., 1 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

3075

247.47M

97.50%

-4.59M

2025Q4

2995

248.62M

97.99%

-4.56M

2025Q3

2933

249.27M

98.24%

-2.14M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Capital World Investors

25.51M

10.04%

-400.40K

-1.55%

Dec 31, 2025

Capital Research Global Investors

17.32M

6.82%

+763.06K

+4.61%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

15.24M

6%

+768.21K

+5.31%

Dec 31, 2025

State Street Investment Management (US)

11.69M

4.6%

+83.54K

+0.72%

Dec 31, 2025

Geode Capital Management, L.L.C.

5.98M

2.35%

+8.16K

+0.14%

Dec 31, 2025

Invesco Capital Management (QQQ Trust)

5.40M

2.12%

-130.10K

-2.35%

Feb 28, 2026

Capital International Investors

4.73M

1.86%

+44.54K

+0.95%

Dec 31, 2025

JP Morgan Asset Management

4.54M

1.79%

+150.76K

+3.44%

Dec 31, 2025

ETFs relacionados



Actualizado: vie., 5 de dic

Nombre

Proporción

VanEck Biotech ETF

9.71%

ProShares Ultra Nasdaq Biotechnology

8.83%

Invesco Nasdaq Biotechnology ETF

8.76%

iShares Biotechnology ETF

7.43%

Invesco Biotechnology & Genome ETF

5.35%

Natixis Loomis Sayles Focused Growth ETF

4.48%

First Trust NASDAQ Pharmaceuticals ETF

4.23%

First Trust NYSE Arca Biotechnology Index Fund

3.5%

Franklin Genomic Advancements ETF

3.33%

Simplify Health Care ETF

3.25%

VanEck Biotech ETF

Proporción9.71%

ProShares Ultra Nasdaq Biotechnology

Proporción8.83%

Invesco Nasdaq Biotechnology ETF

Proporción8.76%

iShares Biotechnology ETF

Proporción7.43%

Invesco Biotechnology & Genome ETF

Proporción5.35%

Natixis Loomis Sayles Focused Growth ETF

Proporción4.48%

First Trust NASDAQ Pharmaceuticals ETF

Proporción4.23%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.5%

Franklin Genomic Advancements ETF

Proporción3.33%

Simplify Health Care ETF

Proporción3.25%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos